# CGRP Inhibition, Autonomic Function, and Migraine

> **NCT04628429** · — · RECRUITING · sponsor: **Medical University of Vienna** · enrollment: 120 (estimated)

## Conditions studied

- Episodic Migraine
- Chronic Migraine

## Interventions

- **DRUG:** Erenumab
- **DRUG:** Galcanezumab
- **DRUG:** Fremanezumab

## Key facts

- **NCT ID:** NCT04628429
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-01
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04628429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04628429, "CGRP Inhibition, Autonomic Function, and Migraine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04628429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*